| Type | Title | Date Released | |
|---|---|---|---|
6-K | POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement | ||
6-K | Pomdoctor Limited Enters Into Debt Conversion Agreement to Issue Class A Ordinary Shares to Satisfy Indebtedness | ||
6-K | POMDOCTOR LIMITED Receives Nasdaq Deficiency Notifications Regarding Market Value and Publicly Held Shares Requirements | ||
6-K | POMdoctor Limited Announces Termination of ADR Program, Share Consolidation, and Direct Nasdaq Listing of Class A Ordinary Shares | ||
6-K | POMDOCTOR LIMITED Receives Nasdaq Staff Delisting Determination Regarding Minimum Bid Price | ||
6-K | Pomdoctor Limited Announces Results of Extraordinary General Meeting of Shareholders | ||
6-K | Pomdoctor Limited Accelerates AI-Enabled Chronic Disease Management and Real-World Data Commercialization | ||
6-K | Pomdoctor Limited Reports Unaudited Condensed Consolidated Financial Statements for the Period Ended June 30, 2026 | ||
6-K | Pomdoctor Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model | ||
6-K | Pomdoctor Limited to Participate in H.C. Wainwright's 28th Annual Global Investment Conference | ||
6-K | POMDOCTOR LIMITED Announces Extraordinary General Meeting to Approve ADR Termination and Share Consolidation | ||
6-K | POMDOCTOR LIMITED Initiates U.S. Market Entry and Expansion Strategy |